Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 18/20 | 0.49 |
| ▸ | TACR1 | P25103 | 3/20 | 0.46 |
| ▸ | CCR5 | P51681 | 2/20 | 0.46 |
| ▸ | PLD2 | O14939 | 2/20 | 0.42 |
| ▸ | PLD1 | Q13393 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL631706 | 1.00 | CCR2 (0.49) | CCR2TACR1CCR5PLD2PLD1 | |
| SCHEMBL631849 | 0.93 | TACR3 (0.47) | CCR2TACR1CCR5PLD2PLD1 | |
| SCHEMBL631850 | 0.93 | TACR3 (0.47) | CCR2TACR1CCR5PLD2PLD1 | |
| SCHEMBL632319 | 0.90 | TACR3 (0.47) | CCR2TACR1PLD2PLD1 | |
| SCHEMBL632320 | 0.90 | TACR3 (0.47) | CCR2TACR1PLD2PLD1 | |
| SCHEMBL5008752 | 0.87 | CCR2 (0.50) | CCR2TACR1CCR5 | |
| SCHEMBL5008751 | 0.87 | CCR2 (0.50) | CCR2TACR1CCR5 | |
| SCHEMBL5003593 | 0.86 | CCR2 (0.54) | CCR2TACR1CCR5PLD2PLD1 | |
| SCHEMBL5003689 | 0.86 | CCR2 (0.52) | CCR2TACR1CCR5PLD2PLD1 | |
| SCHEMBL631802 | 0.83 | CCR2 (0.59) | CCR2TACR1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099806-B1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-02-22 | — | — | EP | claimed |
| US-7470684-B2 | Spiropiperidine derivatives as NK3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2008-12-30 | — | — | US | claimed |
| US-20080176839-A1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-24 | — | — | US | claimed |
| EP-2099806-B1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-7470684-B2 | Spiropiperidine derivatives as NK3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-20080176839-A1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176839-A1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | ADRB3, KCNK3, KCND3 | CCR2 862/4885TACR1 6/4885CCR5 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.